Has Seymour Myers received payments from drug or device companies?

Yes. Drug and device makers reported $1,278 in general payments to Seymour Myers across 44 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Seymour Myers did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Seymour Myers come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Seymour Myers

Family Medicine · la Jolla, CANPI 1083657571

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $595 and has fallen 71.0% since, to $173 in 2023.

$1,278in general payments, 2019–2025

Across 44 payments — averaging $29.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$293
Bayer$216
Teva Pharmaceuticals USA, Inc.$158
Sanofi-aventis U.S. LLC$121
Organogenesis Inc.$57
Alkermes, Inc.$55
plus $377 from 16 others

What the payments were for

Food & beverage$1,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	7	$293
Bayer	6	$216
Teva Pharmaceuticals USA, Inc.	3	$158
Sanofi-aventis U.S. LLC	1	$121
Organogenesis Inc.	2	$57
Alkermes, Inc.	2	$55
Lilly USA, LLC	3	$46
Daiichi Sankyo Inc.	2	$36
Johnson & Johnson	2	$33
Pfizer	2	$30
Merck	2	$29
AstraZeneca	2	$28
Neurocrine Biosciences, Inc.	1	$24
Eisai Inc.	1	$23
Xeris Pharmaceuticals, Inc.	1	$22
Biofrontera Inc.	1	$21
Biohaven Pharmaceuticals, Inc.	1	$18
Kowa Pharmaceuticals America, Inc.	1	$15
Kaleo, Inc.	1	$14
Lucid Diagnostics Inc.	1	$14
Jazz Pharmaceuticals Inc.	1	$12
Zyla Life Sciences, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,278 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Other family medicine in la Jolla

Nisha Bunkela Jolla$89K
Sherly SoleimanEncino$1.2M
Pamela KushnerLos Angeles$1.2M
Sujata NarayanStanford$1.2M
Jeffrey UngerChino$906K
Alexander RivkinLos Angeles$866K
Scott HowellLos Angeles$793K
Derrick ButlerLos Angeles$692K
Sandra CalmanMontara$589K
Anthony JonesOakland$377K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →